SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) and SpayVac for Wildlife, Inc. have announced the completion of SpayVac's new research and production facility in Madison, Wisconsin. The facility will produce long-lasting, single-dose veterinary contraceptive vaccines using a patented liposome-based antigen delivery platform technology licensed from BioVaxys. These vaccines aim to address fertility control needs in wildlife, agricultural production animals, and aquaculture markets.
SpayVac relocated from the University of Victoria, British Columbia, to Madison with support from the BrightStar Wisconsin Foundation and angel investors. The new laboratory will enhance the company's ability to develop new vaccine formulations for various species. SpayVac plans to commercialize fertility control vaccines for deer, horses, and other animals, with regulatory approval filing expected in 2025 and subsequent commercial sales generating royalty revenue for BioVaxys.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) e SpayVac for Wildlife, Inc. hanno annunciato il completamento del nuovo centro di ricerca e produzione di SpayVac a Madison, Wisconsin. Questa struttura produrrà vaccini contraccettivi veterinari a dose singola e a lunga durata utilizzando una tecnologia di consegna di antigeni basata su liposomi, sotto licenza di BioVaxys. Questi vaccini mirano a soddisfare le esigenze di controllo della fertilità nella fauna selvatica, negli animali da produzione agricola e nei mercati dell'acquacoltura.
SpayVac si è trasferita dall'Università di Victoria, British Columbia, a Madison con il supporto della BrightStar Wisconsin Foundation e degli investitori angel. Il nuovo laboratorio rafforzerà la capacità dell'azienda di sviluppare nuove formulazioni vaccinali per diverse specie. SpayVac prevede di comercializzare vaccini per il controllo della fertilità per cervi, cavalli e altri animali, con la presentazione della richiesta di approvazione regolatoria prevista per il 2025 e le vendite commerciali successive che genereranno ricavi da royalty per BioVaxys.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) y SpayVac for Wildlife, Inc. han anunciado la finalización de la nueva instalación de investigación y producción de SpayVac en Madison, Wisconsin. La instalación producirá vacunas anticonceptivas veterinarias de dosis única y de larga duración utilizando una tecnología de entrega de antígenos basada en liposomas, licenciada de BioVaxys. Estas vacunas pretenden abordar las necesidades de control de la fertilidad en la vida silvestre, los animales de producción agrícola y los mercados de acuicultura.
SpayVac se trasladó de la Universidad de Victoria, Columbia Británica, a Madison con el apoyo de la BrightStar Wisconsin Foundation y de inversores ángeles. El nuevo laboratorio mejorará la capacidad de la empresa para desarrollar nuevas formulaciones de vacunas para diversas especies. SpayVac planea comercializar vacunas de control de la fertilidad para ciervos, caballos y otros animales, esperando presentar la solicitud de aprobación regulatoria en 2025 y que las subsiguientes ventas comerciales generen ingresos por regalías para BioVaxys.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF)와 SpayVac for Wildlife, Inc.는 위스콘신주 매디슨에 위치한 SpayVac의 새로운 연구 및 생산 시설의 완료를 발표했습니다. 이 시설은 장기 지속형 단일 용량 수의학적 피임 백신을 생산하며, BioVaxys로부터 라이선스 받은 지질체 기반 항원 전달 플랫폼 기술을 사용합니다. 이 백신은 야생 동물, 농업 생산 동물 및 양식 시장의 생식 통제 요구에 대응하는 것을 목표로 합니다.
SpayVac은 브리티시컬럼비아주 빅토리아 대학교에서 매디슨으로 이전하였으며, BrightStar Wisconsin Foundation과 엔젤 투자자들의 지원을 받았습니다. 새로운 실험실은 다양한 종을 위한 새로운 백신 제형 개발 능력을 높일 것입니다. SpayVac은 사슴, 말 및 기타 동물을 위한 생식 통제 백신을 상용화할 계획이며, 2025년에 규제 승인 신청서를 제출할 예정이며, 이후 상업 판매로 BioVaxys에 대한 로열티 수익이 발생할 것으로 기대하고 있습니다.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) et SpayVac for Wildlife, Inc. ont annoncé l'achèvement de la nouvelle installation de recherche et de production de SpayVac à Madison, Wisconsin. Cette installation produira des vaccins contraceptifs vétérinaires à dose unique et de longue durée en utilisant une technologie de délivrance d'antigènes basée sur des liposomes, sous licence de BioVaxys. Ces vaccins visent à répondre aux besoins de contrôle de la fertilité dans la faune, les animaux de production agricole et l'aquaculture.
SpayVac a déménagé de l'Université de Victoria, en Colombie-Britannique, à Madison, avec le soutien de la BrightStar Wisconsin Foundation et d'investisseurs providentiels. Le nouveau laboratoire améliorera la capacité de l'entreprise à développer de nouvelles formulations de vaccins pour diverses espèces. SpayVac prévoit de commercialiser des vaccins de contrôle de la fertilité pour les cerfs, les chevaux et d'autres animaux, avec une demande d'approbation réglementaire attendue en 2025 et des ventes commerciales ultérieures générant des revenus de redevance pour BioVaxys.
BioVaxys Technology Corp. (CSE: BIOV, OTCQB: BVAXF) und SpayVac for Wildlife, Inc. haben den Abschluss der neuen Forschungs- und Produktionsanlage von SpayVac in Madison, Wisconsin, bekannt gegeben. Die Einrichtung wird langanhaltende, einmalige veterinärmedizinische Verhütungsimpfstoffe unter Verwendung einer patentierten, liposomenbasierten Antigenabgabetechnologie, die von BioVaxys lizenziert wurde, herstellen. Diese Impfstoffe zielen darauf ab, die Bedürfnisse der Fertilitätskontrolle in der Wildtier-, landwirtschaftlichen Produktions- und Aquakulturbranche anzusprechen.
SpayVac zog von der Universität Victoria, British Columbia, nach Madison um, unterstützt von der BrightStar Wisconsin Foundation und Angel-Investoren. Das neue Labor wird die Fähigkeit des Unternehmens steigern, neue Impfstoffformulierungen für verschiedene Arten zu entwickeln. SpayVac plant, Fertilitätskontrollimpfstoffe für Rehe, Pferde und andere Tiere zu kommerzialisieren, wobei die Einreichung der Genehmigungsanträge für 2025 vorgesehen ist und die anschließenden kommerziellen Verkäufe Lizenzgebühren für BioVaxys generieren werden.
- Completion of new research and production facility in Madison, Wisconsin
- Potential for commercialization of fertility control vaccines for multiple species
- Expected regulatory approval filing in 2025
- Anticipated royalty revenue for BioVaxys from future commercial sales
- None.
SpayVac® uses a patented liposome-based antigen delivery platform technology, licensed from BioVaxys (https://www.biovaxys.com/), which has demonstrated a robust and sustained immune response in several species. SpayVac single-dose vaccines will address the fertility-control needs in wildlife, agricultural production animals, and aquaculture markets.
SpayVac for Wildlife, Inc. initially operated out of the University of
"This new laboratory will significantly enhance our ability to develop new vaccine formulations for species that would benefit from humane, long-term fertility control," said Dr. Ursula Bechert, Vice-President of Research and Development for SpayVac for Wildlife. Tom D'Orazio, CEO of SpayVac for Wildlife, shared, "I'm enthusiastic about the many benefits of this space. It is flexible enough for us to do both our research and small-scale production. The Lytic facility has a number other biopharma tenant companies, such as Kendrick Laboratories and Plumb Pharmaceuticals, creating a biotech hub and collaborative environment."
SpayVac is planning to soon commercialize fertility control vaccines for deer, horses and other animals that are also based on the patented liposome-based delivery-platform technology licensed from BioVaxys.
Kenneth Kovan, BioVaxys President & Chief Operating Officer, stated, "With our licensee SpayVac on track for submitting their filing for regulatory approval in 2025, they expect to see commercial sales, which will generate royalty revenue from our liposome-based antigen delivery platform technology."
About SpayVac for Wildlife, Inc.
SpayVac for Wildlife, Inc., (https://spayvac.com/) based in
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a clinical stage biopharmaceutical company registered in
BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
BioVaxys Technology Corp.
+1 646 452 7054
ON BEHALF OF THE BOARD
Signed "Dr. Ursula Bechert"
Dr. Ursula Bechert, VP Research & Development
SpayVac for Wildlife, Inc.
+1 877 510 6812
Logo: https://mma.prnewswire.com/media/2415135/4832936/BioVaxys_Technology_Corp_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/spayvac-for-wildlife-inc-announces-completion-of-spayvac-research-and-production-facility-in-madison-wisconsin-302225118.html
SOURCE BioVaxys Technology Corp.
FAQ
What is the purpose of SpayVac's new facility in Madison, Wisconsin?
When does SpayVac plan to file for regulatory approval for its fertility control vaccines?
How will BioVaxys (BVAXF) benefit from SpayVac's commercialization of fertility control vaccines?
What species are targeted for SpayVac's fertility control vaccines?
